BusinessAxsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental NeurotherapeuticsBy Nasdaq OMXMar 12, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease AgitationBy Nasdaq OMXJul 17, 2017, 11:00 AM UTC
